Dendritic cells are antigen-presenting cells that are essential for the activation and proliferation of T cells. These cells can be used as a highly efficient anticancer treatment, but are extremely expensive. Current artificial dendritic cells are not as efficient due to inefficient multivalent binding of the antigens presented. This project aims to develop a more efficient synthetic dendritic cell by manipulation of the multivalency and molarity of the effector molecules (aCD3, aCD28 and cytokines) on a semiflexible polymer to facilitate effective T cell activation.

  Are you interested in a PhD at the AIBN? Click here, and start your journey today. 

Dendritic cells, T cells, cancer, antigens, polymer,

Supervisor name/s

Professor Alan Rowan
AIBN Institute Director
Rowan Group

Dr Amanda Kijas
Senior Research Fellow
Rowan Group

Supervisor email/s